TABLE 1.
HIV drug resistance genotyping results April 2022.
| Drug class | Drug resistance mutations | Drug name | Resistance level | Mutation score |
|---|---|---|---|---|
| PI major | None | ATV | Susceptible | 0 |
| DRV | Susceptible | 0 | ||
| PI accessory | L23LI | LPV | Susceptible | 0 |
| NRTI | M184V | ABC | Low-level resistance | 15 |
| AZT | Susceptible | -10 | ||
| 3TC | High-level resistance | 60 | ||
| FTC | High-level resistance | 60 | ||
| TDF | Susceptible | -10 | ||
| NNRTI | None | EFV | Susceptible | 0 |
| RPV | Susceptible | 0 | ||
| ETR | Susceptible | 0 | ||
| InSTI major | T66TI, G118R, E138K | DTG | High-level resistance | 75 |
| InSTI minor | M50I | RAL | High-level resistance | 100 |
| CAB | High-level resistance | 90 | ||
| BIC | Intermediate resistance | 55 |
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; BIC, bictegravir; CAB, cabotegravir; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; InSTI, integrase strand transfer inhibitor; LPV, lopinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir.